半年前，FDA、CDC押的寶

來源: fuz 於 2022-11-13 05:47:44 [檔案] [博客] [舊帖] [給我悄悄話] 本文已被閱讀：次 (7047 bytes)

本文內容已被 [ fuz ] 在 2022-11-13 07:16:29 編輯過。如有問題，請報告版主或論壇管理刪除.

回答: 根據CDC檢測的樣本，目前流感的主導病毒是H3N2（占75%）由 dudaan 於 2022-11-13 05:33:55

https://www.cdc.gov/mmwr/volumes/71/wr/mm7129a1.htm

Composition of the 2022–23 Influenza Vaccines

Vaccine strains for the 2022–23 influenza vaccines were selected by the Food and Drug Administration’s Vaccines and Related Biologic Products Advisory Committee based on WHO’s recommended Northern Hemisphere 2022–23 influenza vaccine composition. No changes were made to the A(H1N1)pdm09 or the B/Yamagata egg-based, cell-based, or recombinant vaccine recommended components. The recommended A(H3N2) component was changed to an A/Darwin/9/2021 (H3N2)–like virus for egg-based vaccines and an A/Darwin/6/2021 (H3N2)–like virus for cell-based or recombinant vaccines. The B/Victoria component recommendation was changed to a B/Austria/1359417/2021–like virus (3,4). The clade and subclade for the recommended vaccine strains were 6b.1A.5a.2 for A(H1N1)pdm09, 3C.2a1b.2a.2 for A(H3N2), V1A.3a.2 for B/Victoria, and Y3 for B/Yamagata.

https://www.fda.gov/vaccines-blood-biologics/lot-release/influenza-vaccine-2022-2023-season

（四聯蛋胚疫苗）

The committee recommended that the quadrivalent formulation of egg-based influenza vaccines for the U.S. 2022-2023 influenza season contain the following:

an A/Victoria/2570/2019 (H1N1)pdm09-like virus;
an A/Darwin/9/2021 (H3N2)-like virus;
a B/Austria/1359417/2021-like virus (B/Victoria lineage); and
a B/Phuket/3073/2013-like virus (B/Yamagata lineage).

（四聯重組疫苗）

The committee recommended that the quadrivalent formulation of cell- or recombinant-based influenza vaccines for the U.S. 2022-2023 influenza season contain the following:

an A/Wisconsin/588/2019 (H1N1)pdm09-like virus;
an A/Darwin/6/2021 (H3N2)-like virus;
a B/Austria/1359417/2021-like virus (B/Victoria lineage); and
a B/Phuket/3073/2013-like virus (B/Yamagata lineage).

（三聯疫苗）

For trivalent influenza vaccines for use in the U.S. for the 2022-2023 influenza season, depending on the manufacturing method of the vaccine, the committee recommended that the A(H1N1)pdm09, A(H3N2) and B/Austria/1359417/2021-like virus (B/Victoria lineage) viruses recommended above for the quadrivalent vaccines be used.